JHP
WST icon

James Hambro & Partners’s West Pharmaceutical WST Stock Holding History

James Hambro & Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-957
Closed -$290K – 70
2022
Q2 		$290K Hold
957
– – 0.02% 52
2022
Q1 		$394K Hold
957
– – 0.03% 50
2021
Q4 		$449K Hold
957
– – 0.03% 50
2021
Q3 		$406K Hold
957
– – 0.03% 61
2021
Q2 		$344K Buy
+957
New +$316K 0.03% 71

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

James Hambro & Partners's WST Position: Q3 2022 in Review

James Hambro & Partners sold out of West Pharmaceutical (WST) in Q3 2022, closing a stake of 957 shares — an estimated $290K sold.

James Hambro & Partners first reported a position in WST in Q2 2021 and held it in 5 quarters. The position peaked at $449K in Q4 2021. 638 funds tracked by Wall St. Rank hold WST as of Q3 2022.

  • James Hambro & Partners reported no remaining West Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • James Hambro & Partners sold 957 West Pharmaceutical shares in Q3 2022, an estimated $290K.
  • James Hambro & Partners first reported a position in West Pharmaceutical in Q2 2021 and held it in 5 quarters.
  • James Hambro & Partners's West Pharmaceutical position peaked at $449K in Q4 2021.
  • 638 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on James Hambro & Partners's 13F filing for Q3 2022, filed 20 Oct 2022.